Aquestive Therapeutics officer plans roughly $25.8K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. officer Matthew W. Davis filed notice of an intended sale of 7,197 common shares, with an approximate aggregate market value of $25,765.26. The approximate sale date is November 12, 2026. Davis acquired the shares from the issuer as restricted stock units on November 10, 2026. The notice lists May 26, 2026 as the Rule 10b5-1 plan adoption or instruction date and names Morgan Stanley Smith Barney LLC as broker.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.